menu
    • menu
    [{"orgOrder":0,"company":"Myung In Pharm","sponsor":"Pharma Two B","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"ISRAEL","productType":"Small molecule","year":"2021","type":"Licensing Agreement","leadProduct":"Pramipexole Dihydrochloride","moa":"D2 receptor","graph1":"Neurology","graph2":"Phase III","graph3":"Myung In Pharm","amount2":0.01,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0.01,"dosageForm":"Capsule","sponsorNew":"Myung In Pharm \/ Myung In Pharm Co. Ltd","highestDevelopmentStatusID":"10","companyTruncated":"Myung In Pharm \/ Myung In Pharm Co. Ltd"},{"orgOrder":0,"company":"Myung In Pharm","sponsor":"Luye Pharma","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"CHINA","productType":"Small molecule","year":"2024","type":"Partnership","leadProduct":"Rivastigmine","moa":"","graph1":"Neurology","graph2":"Approved","graph3":"Myung In Pharm","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Patch","sponsorNew":"Myung In Pharm \/ Myung In Pharm","highestDevelopmentStatusID":"12","companyTruncated":"Myung In Pharm \/ Myung In Pharm"}]

    Find Clinical Drug Pipeline Developments & Deals by Myung In Pharm

    Menu

    Myung In Pharm

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Myung In Pharm

                            South Korea arrow
                            Antibody Engineering
                            Not Confirmed

                            Myung In Pharm

                            South Korea arrow
                            Antibody Engineering
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Rivastigmine

                            Therapeutic Area : Neurology

                            Study Phase : Approved

                            Recipient : Luye Pharma

                            Deal Size : Undisclosed

                            Deal Type : Partnership

                            DEALS_DEV arrow-down

                            Luye Pharma Grants Myung In Pharm Exclusive Rights For Rivastigmine Patch In South Korea

                            Details : The partnership aims to develop and commercialise of Rivalif (rivastigmine) twice weekly transdermal patch in South Korea for mild to moderate dementia associated with Alzheimer's disease.

                            Brand Name : Rivalif

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            February 05, 2024

                            Lead Product(s) : Rivastigmine

                            Therapeutic Area : Neurology

                            Highest Development Status : Approved

                            Recipient : Luye Pharma

                            Deal Size : Undisclosed

                            Deal Type : Partnership

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Myung In Pharm

                            South Korea arrow
                            Antibody Engineering
                            Not Confirmed

                            Myung In Pharm

                            South Korea arrow
                            Antibody Engineering
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Pramipexole Dihydrochloride,Rasagiline Mesylate

                            Therapeutic Area : Neurology

                            Study Phase : Phase III

                            Recipient : Pharma Two B

                            Deal Size : $5.0 million

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            Pharma Two B Announces Licensing and Investment Agreement with Myung In Pharm (MIP) for P2B001 in South Korea

                            Details : Under the terms of the agreement, Myung In Pharm will seek regulatory approval for P2B001 in South Korea and will manufacture, commercialize and distribute P2B001 in the region.

                            Brand Name : P2B001

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            November 18, 2021

                            Lead Product(s) : Pramipexole Dihydrochloride,Rasagiline Mesylate

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase III

                            Recipient : Pharma Two B

                            Deal Size : $5.0 million

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth